163 related articles for article (PubMed ID: 14982944)
1. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis.
Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA
J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism.
Murray JC; Symonds P; Ward W; Huggins M; Tiga A; Rice K; Heng YM; Todd I; Robins RA
J Immunol; 2004 Jan; 172(1):274-81. PubMed ID: 14688335
[TBL] [Abstract][Full Text] [Related]
3. Cell-surface associated p43/endothelial-monocyte-activating-polypeptide-II in hepatocellular carcinoma cells induces apoptosis in T-lymphocytes.
Faisal W; Symonds P; Panjwani S; Heng Y; Murray JC
Asian J Surg; 2007 Jan; 30(1):13-22. PubMed ID: 17337366
[TBL] [Abstract][Full Text] [Related]
4. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
[TBL] [Abstract][Full Text] [Related]
5. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress.
Barnett G; Jakobsen AM; Tas M; Rice K; Carmichael J; Murray JC
Cancer Res; 2000 Jun; 60(11):2850-7. PubMed ID: 10850427
[TBL] [Abstract][Full Text] [Related]
6. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.
van Horssen R; Eggermont AM; ten Hagen TL
Cytokine Growth Factor Rev; 2006 Oct; 17(5):339-48. PubMed ID: 16945568
[TBL] [Abstract][Full Text] [Related]
7. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
8. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.
van Horssen R; Rens JA; Schipper D; Eggermont AM; ten Hagen TL
Apoptosis; 2006 Dec; 11(12):2137-45. PubMed ID: 17051333
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
10. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Kayton ML; Libutti SK
Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
Berger AC; Alexander HR; Wu PC; Tang G; Gnant MF; Mixon A; Turner ES; Libutti SK
Cytokine; 2000 Jul; 12(7):992-1000. PubMed ID: 10880244
[TBL] [Abstract][Full Text] [Related]
12. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
Lans TE; Van Horssen R; Eggermont AM; Ten Hagen TL
Anticancer Res; 2004; 24(4):2243-8. PubMed ID: 15330168
[TBL] [Abstract][Full Text] [Related]
13. Regulation of EMAP II by hypoxia.
Matschurat S; Knies UE; Person V; Fink L; Stoelcker B; Ebenebe C; Behrensdorf HA; Schaper J; Clauss M
Am J Pathol; 2003 Jan; 162(1):93-103. PubMed ID: 12507893
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induced by a corneal-endothelium-derived cytokine.
Liu SH; Gottsch JD
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3152-9. PubMed ID: 10586937
[TBL] [Abstract][Full Text] [Related]
15. Endothelial-monocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3.
Hou Y; Plett PA; Ingram DA; Rajashekhar G; Orschell CM; Yoder MC; March KL; Clauss M
Exp Hematol; 2006 Aug; 34(8):1125-32. PubMed ID: 16863920
[TBL] [Abstract][Full Text] [Related]
16. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.
Tandle AT; Mazzanti C; Alexander HR; Roberts DD; Libutti SK
Cytokine; 2005 Jun; 30(6):347-58. PubMed ID: 15935955
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of endothelial-monocyte-activating polypeptide-II expression in vivo.
Murray JC; Barnett G; Tas M; Jakobsen A; Brown J; Powe D; Clelland C
Am J Pathol; 2000 Dec; 157(6):2045-53. PubMed ID: 11106577
[TBL] [Abstract][Full Text] [Related]
18. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury.
Nührenberg TG; Langwieser N; Schwarz JB; Hou Y; Frank P; Sorge F; Matschurat S; Seidl S; Kastrati A; Schömig A; Clauss MA; Zohlnhöfer D
Cardiovasc Res; 2008 Feb; 77(3):580-9. PubMed ID: 18029408
[TBL] [Abstract][Full Text] [Related]
19. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
Schwarz RE; Schwarz MA
J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
[TBL] [Abstract][Full Text] [Related]
20. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH.
Chang SY; Ko HJ; Heo TH; Kang CY
Mol Pharmacol; 2005 May; 67(5):1534-43. PubMed ID: 15710745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]